Beneficial Effect of Fenofibrate and Silymarin on Hepatic Steatosis and Gene Expression of Lipogenic and Cytochrome P450 Enzymes in Non-Obese Hereditary Hypertriglyceridemic Rats
Open Access
- 26 April 2022
- journal article
- research article
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 44 (5) , 1889-1900
Abstract
The efficacy of fenofibrate in the treatment of hepatic steatosis has not been clearly demonstrated. In this study, we investigated the effects of fenofibrate and silymarin, administered as monotherapy and in combination to existing hepatic steatosis in a unique strain of hereditary hypertriglyceridemic rats (HHTg), a non-obese model of metabolic syndrome. HHTg rats were fed a standard diet without or with fenofibrate (100 mg/kg b.wt./day) or with silymarin (1%) or with a combination of fenofibrate with silymarin for four weeks. Fenofibrate alone and in combination with silymarin decreased serum and liver triglycerides and cholesterol and increased HDL cholesterol. These effects were associated with the decreased gene expression of enzymes involved in lipid synthesis and transport, while enzymes of lipid conversion were upregulated. The combination treatment had a beneficial effect on the gene expression of hepatic cytochrome P450 (CYP) enzymes. The expression of the CYP2E1 enzyme, which is source of hepatic reactive oxygen species, was reduced. In addition, fenofibrate-induced increased CYP4A1 expression was decreased, suggesting a reduction in the pro-inflammatory effects of fenofibrate. These results show high efficacy and mechanisms of action of the combination of fenofibrate with silymarin in treating hepatic steatosis and indicate the possibility of protection against disorders in which oxidative stress and inflammation are involved.Keywords
Funding Information
- Univerzita Palackého v Olomouci (IGA_LF_2022_006)
- Institute of Clinical and Experimental Medicine (IN 00023001)
This publication has 59 references indexed in Scilit:
- Non‐alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: Results of a US national survey in three ethnic groupsJournal of Gastroenterology and Hepatology, 2013
- Fatty acid synthase and liver triglyceride metabolism: Housekeeper or messenger?Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2012
- The Effect of CYP7A1 Polymorphisms on Lipid Responses to FenofibrateJournal of Cardiovascular Pharmacology, 2012
- P-glycoprotein Dysfunction Contributes to Hepatic Steatosis and Obesity in MicePLOS ONE, 2011
- Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2010
- Fenofibrate Simultaneously Induces Hepatic Fatty Acid Oxidation, Synthesis, and Elongation in MiceJournal of Biological Chemistry, 2009
- Hypolipidemic effects of silymarin are not mediated by the peroxisome proliferator-activated receptor alphaXenobiotica, 2007
- PPARα activation increases triglyceride mass and adipose differentiation-related protein in hepatocytesJournal of Lipid Research, 2006
- Phenolics-rich extracts from Silybum marianum and Prunella vulgaris reduce a high-sucrose diet induced oxidative stress in hereditary hypertriglyceridemic ratsPharmacological Research, 2004
- The Enzymes, Regulation, and Genetics of Bile Acid SynthesisAnnual Review of Biochemistry, 2003